My major research interest is in radiation therapy for lymphomas, genitourinary cancers—including prostate cancer, bladder cancer and seminoma—and late effects of treatment, especially second cancers. Current research activities include study of image guided precision radiotherapy. I also have a long-standing interest in cancer classification with an emphasis on staging and prognostic factors. In addition, my current interests include the application of modern information and communication technologies in cancer control.
Mary K Gospodarowicz
Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496.
J Clin Oncol. 2011 May 20;29(15_suppl):8035
A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013).
J Clin Oncol. 2011 May 20;29(15_suppl):4514
J Clin Oncol. 2011 May 20;29(15_suppl):4565
Development of clinical research process metrics and tracking improvement in quality assurance in clinical trials.
J Clin Oncol. 2011 May 20;29(15_suppl):e16572
Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone.
J Clin Oncol. 2004 Jul 15;22(14_suppl):6521
J Clin Oncol. 2004 Jul 15;22(14_suppl):4519
A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013.
J Clin Oncol. 2011 Mar;29(7_suppl):3
J Clin Oncol. 2011 Mar;29(7_suppl):20
Clin Oncol (R Coll Radiol). 2016 Dec 05;:
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Professor, Department of Radiation Oncology, University of Toronto
President, Union for International Cancer Control (UICC)